Find Funding Opportunities

 COVID-19 Funding Notices | Approved Initiative Concepts | Research Opportunity Announcements

All NINDS-related notices of funding opportunities (NOFOs), request for applications (RFAs), program announcements (PAs), and other NIH Guide announcements are listed. Search the Closed Opportunities tab to find expired opportunities. Search the Notices tab to find all Notices.

Learn more about award types and program directors and managers.

NINDS has a number of open positions for researchers and clinicians to contribute to exciting neuroscience programs - APPLY NOW!

For more focused results add quotes to indicate parameters. Example format: "search term".

Expiration Date: Saturday, May 8, 2027 NOFO Number: PAR-24-092 Release Date: Monday, December 11, 2023 Notice Type: PAR
This NOFO invites applications at the intersection of HIV and aging by proposing research that aims to meet the following objectives: 1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) Improve approaches for testing, preventing, and treating HIV infection, and managing HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying current aging science approaches. Proposed research must be consistent with the HIV/AIDS Research Priorities outlined by NIHs Office of AIDS Research (OAR), as described inNOT-OD-20-018.
Expiration Date: Saturday, May 8, 2027 NOFO Number: PAR-24-091 Release Date: Monday, December 11, 2023 Notice Type: PAR
This NOFO invites applications at the intersection of HIV and aging by proposing research that aims to meet the following objectives: 1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) Improve approaches for testing, preventing, and treating HIV infection, and managing HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying current aging science approaches. Proposed research must be consistent with the HIV/AIDS Research Priorities outlined by NIHs Office of AIDS Research (OAR), as described inNOT-OD-20-018.
Expiration Date: Wednesday, October 1, 2025 NOFO Number: NOT-OD-24-038 Release Date: Friday, December 8, 2023 Notice Type: Notice of Special Interest
The National Institutes of Health (NIH) vision for womens health is a world in which the influences of sex and gender are rigorously integrated into the health research enterprise. For the purposes of this Notice, sex refers to a set of biological variables, including anatomy, physiology, genetics, and hormones. For the purposes of this Notice, gender refers to a set of social and structural variables that encompass gender identity and expression, gender roles and norms, gender relations, and gender power systems (e.g., structural sexism). Sex-linked biology and gender-related factors can act independently or interactively to influence health. As a social, cultural, and structural construct, gender encompasses multiple domains. Many other social variablesincluding race, ethnicity, disability, sexual orientation, socioeconomic status, and educationintersect with gender to impact health and disease in unique ways. Intersectional frameworks enable consideration of how these socially determined categories overlap and interact to create disparate and inequitable outcomes for individuals and communities. The NIH Office of Research on Womens Health (ORWH) and our Institute, Center, and Office (ICO) partners are issuing this Notice to highlight interest in receiving research and training grant applications focused on health impacts of gender-related social and structural variables. For this Notice, relevant domains of gender are gender roles and norms, gender relations, gender equity/inequity, gender equality/inequality, gender-related power dynamics, and structural sexism. Applications can consider one or more domains as they relate to health.
Expiration Date: Saturday, March 2, 2024 NOFO Number: RFA-MH-25-116 Release Date: Tuesday, November 28, 2023 Notice Type: RFA
This Notice of Funding Opportunity (NOFO) solicits applications to create a Marmoset Coordination Center. The awardee will be responsible for two separate but related activities. The first activity will be to become the repository for genomic, pedigree, and event records (date of birth, medical, reproductive history) for captive marmosets. The awardee is expected to use that information to help make breeding recommendations to maximize the health and genetic diversity of the marmosets in primate colonies. Applicants are encouraged to adopt the model used by the Association of Zoos and Aquariums.
Expiration Date: Saturday, March 2, 2024 NOFO Number: RFA-MH-25-115 Release Date: Tuesday, November 28, 2023 Notice Type: RFA
The common marmoset (Callithrix jacchus) has emerged as a promising nonhuman primate model system to understand the primate brain. This has come about both from the realization that the behavior of the common marmoset is similar in some ways to human behavior and from recent demonstration of germline transmission of exogenous genetic information. This Notice of Funding Opportunity (NOFO) solicits applications to expand existing colonies of the common marmoset for neuroscience research in the United States, and to support the care, breeding and distribution of genetically modified marmosets, and cryopreserved embryos and gametes created by NIH-funded research programs such as the NIH BRAIN Initiative Tools for Germline Gene Editing in Marmosets research consortium. Recipients s under this NOFO are expected to expand their current marmoset colonies to provide healthy, well-characterized animals that will be made available to the neuroscience research community, and to include a plan to accept genetically modified marmosets, and cryopreserved embryos and gametes for distribution to the research community. Recipients are also expected to participate in and provide health and genetic information to an NIH-Funded Marmoset Coordination Center to help the community understand the pedigree of individuals in the captive marmoset population and improve the genetic diversity of that population across multiple colonies.
Expiration Date: Sunday, September 6, 2026 NOFO Number: PAR-23-311 Release Date: Monday, November 27, 2023 Notice Type: PAR
(Reissue of PAR-21-266) The purpose of this funding opportunity announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The projects must focus on products related to the mission and goals of the NINDS and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies. Only SBIR Phase II and Fast-Track applications are supported under this program. SBIR Phase I applications are only accepted as part of a Fast-track application.
Expiration Date: Sunday, September 6, 2026 NOFO Number: PAR-24-044 Release Date: Monday, November 27, 2023 Notice Type: PAR
(Reissue of PAR-18-617) The purpose of this funding opportunity announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Technology Transfer (STTR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The projects must focus on products related to the mission and goals of the NINDS and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies. Only STTR Phase II and Fast-Track applications are supported under this program. STTR Phase I applications are only accepted as part of a Fast-track application.
Expiration Date: Wednesday, August 19, 2026 NOFO Number: PAR-24-043 Release Date: Thursday, November 2, 2023 Notice Type: PAR
Reissue of PAR-18-546. The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.
Expiration Date: Wednesday, August 19, 2026 NOFO Number: PAR-24-063 Release Date: Wednesday, November 1, 2023 Notice Type: PAR
Reissue of PAR-18-541. The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.
Expiration Date: Monday, November 30, 2026 NOFO Number: NOT-AA-23-020 Release Date: Wednesday, November 1, 2023 Notice Type: Notice of Special Interest
This Notice encourages eligible awardees in the BRAIN Initiative community to apply for administrative supplements in response to PA-23-189, Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed). The NIH has a strong interest in the diversity of the NIH-funded workforce (see NOT-OD-20-031) and encourages institutions to prioritize inclusion by supporting the participation of individuals from groups identified as underrepresented in the biomedical, clinical, behavioral, and social sciences.
Export to:
A maximum of 400 records can be exported.